Net Loss per Share (As Restated) (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Schedule of Antidilutive Shares Excluded From Calculation of Diluted Net Loss Per Share

The following table presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share of Common Stock attributable to common stockholders because their effect was anti-dilutive:

	March 31, 2023 (As Restated)	March 31, 2022
Shares issuable upon exercise of SPA Warrants	93,571,419	—
Shares issuable upon conversion of notes and settlement of Make-Whole provisions	311,952,117	9,009,210
Other warrants	29,454,593	4,544,258
Stock-based compensation awards – Options	37,181,872	43,781,815
Stock-based compensation awards – RSUs	20,131,111	—
Public warrants	23,540,988	22,977,568
Private warrants	111,131	674,551
Total	515,943,231	80,987,402